Meyer, J. M. (2014). A rational approach to employing high plasma levels of antipsychotics for violence associated with schizophrenia: case vignettes. CNS Spectr, 19, 432–438.CrossRefGoogle ScholarPubMed

Meyer, J. M., Cummings, M. A., Proctor, G., et al. (2016). Psychopharmacology of persistent violence and aggression. Psychiatr Clin North Am, 39, 541–556.CrossRefGoogle ScholarPubMed

Meyer, J. M. (2018). Pharmacotherapy of psychosis and mania. In Gilman: The Pharmacological Basis of Therapeutics (eds.). New York: McGraw-Hill.Google Scholar

Schoretsanitis, G., Kane, J. M., Correll, C. U., et al. (2020). Blood levels to optimize antipsychotic treatment in clinical practice: a joint consensus statement of the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie. J Clin Psychiatry, 81(3), 19cs13169.CrossRefGoogle ScholarPubMed

Castro, V. M., Roberson, A. M., McCoy, T. H., et al. (2016). Stratifying risk for renal insufficiency among lithium-treated patients: an electronic health record study. Neuropsychopharmacol, 41, 1138–1143.CrossRefGoogle ScholarPubMed

Meyer, J. M. (2018). Gilman: The Pharmacological Basis of Therapeutics. Pharmacotherapy of Psychosis and Mania. New York: McGraw-Hill.Google Scholar

Beach, S. R., Celano, C. M., Noseworthy, P. A., et al. (2013). QTc prolongation, Torsades de Pointes, and psychotropic medications. Psychosomatics, 54, 1–13.CrossRefGoogle ScholarPubMed

Trinkley, K. E., Page, R. L., 2nd, Lien, H., et al. (2013). QT interval prolongation and the risk of Torsades de Pointes: essentials for clinicians. Curr Med Res Opin, 29, 1719–1726.CrossRefGoogle ScholarPubMed

Day, R. O., Snowden, L., McLachlan, A. J. (2017). Life-threatening drug interactions: what the physician needs to know. Intern Med J, 47, 501–512.CrossRefGoogle ScholarPubMed

Voigt, N., Ort, K., Sossalla, S. (2019). Drug-drug interactions you should know!. Fortschr Neurol Psychiatr, 87, 320–332.Google ScholarPubMed

Wald, A. (2015). Constipation: pathophysiology and management. Curr Opin Gastroenterol, 31, 45–49.Google Scholar

Prichard, D. O., Bharucha, A. E. (2018). Recent advances in understanding and managing chronic constipation. F1000Res, 7, 1640.CrossRefGoogle ScholarPubMed

Hofmann, W. P., Radle, J., Moench, C., et al. (2008). Prediction of perioperative mortality in patients with advanced liver disease and abdominal surgery by the use of different scoring systems and tests. Z Gastroenterol, 46, 1283–1289.CrossRefGoogle ScholarPubMed

Tsoris, A., Marlar, C. A. (2020). Use of the child Pugh score in liver disease. In StatPearls (eds.). Treasure Island, FL: StatPearls Publishing LLC.Google Scholar

Kook, K. A., Stimmel, G. L., Wilkins, J. N., et al. (1985). Accuracy and safety of a priori lithium loading. J Clin Psychiatry, 46, 49–51.Google ScholarPubMed

Hirschfeld, R. M., Baker, J. D., Wozniak, P., et al. (2003). The safety and early efficacy of oral-loaded divalproex versus standard-titration divalproex, lithium, olanzapine, and placebo in the treatment of acute mania associated with bipolar disorder. J Clin Psychiatry, 64, 841–846.Google Scholar

Tohen, M., Ketter, T. A., Zarate, C. A., et al. (2003). Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry, 160, 1263–1271.CrossRefGoogle ScholarPubMed

Bakker, I. C., Schubart, C. D., Zelissen, P. M. (2016). Successful treatment of a prolactinoma with the antipsychotic drug aripiprazole. Endocrinol Diabetes Metab Case Rep, 2016, 160028.Google ScholarPubMed

Grigg, J., Worsley, R., Thew, C., et al. (2017). Antipsychotic-induced hyperprolactinemia: synthesis of world-wide guidelines and integrated recommendations for assessment, management and future research. Psychopharmacology (Berl), 234, 3279–3297.CrossRefGoogle ScholarPubMed

Gonzalez-Rodriguez, A., Labad, J., Seeman, M. V. (2020). Antipsychotic-induced hyperprolactinemia in aging populations: prevalence, implications, prevention and management. Prog Neuropsychopharmacol Biol Psychiatry, 101, 109941.CrossRefGoogle ScholarPubMed

Marik, P. E., Varon, J. (2007). Hypertensive crises: challenges and management. Chest, 131, 1949–1962.CrossRefGoogle ScholarPubMed

Burton, T. J., Wilkinson, I. B. (2008). The dangers of immediate-release nifedipine in the emergency treatment of hypertension. J Hum Hypertens, 22, 301–302.CrossRefGoogle ScholarPubMed

Yilmaz, S., Pekdemir, M., Tural, U., et al. (2011). Comparison of alprazolam versus captopril in high blood pressure: a randomized controlled trial. Blood Press, 20, 239–243.CrossRefGoogle ScholarPubMed

Meyer, J. M. (2017). A concise guide to monoamine oxidase inhibitors: part 1. Current Psychiatry, 16, 14–16.Google Scholar

Gillman, P. K. (2020). Monoamine oxidase inhibitors: a review concerning dietary tyramine and drug interactions. PsychoTropical Commentaries, PsychoTropical Research, Bucasia, Queensland, Australia. Available at: psychotropical.com/maois-diet-drug-interactions (last accessed November 13, 2020).Google Scholar

Gillman, P. K. (2003). Mirtazapine: unable to induce serotonin toxicity? Clin Neuropharmacol, 26, 288–289; author reply 289–290.CrossRefGoogle ScholarPubMed

Gillman, P. K. (2006). A systematic review of the serotonergic effects of mirtazapine in humans: implications for its dual action status. Human Psychopharmacol, 21, 117–125.CrossRefGoogle ScholarPubMed

Quante, A., Zeugmann, S. (2012). Tranylcypromine and bupropion combination therapy in treatment-resistant major depression: a report of 2 cases. J Clin Psychopharmacol, 32, 572–574.CrossRefGoogle Scholar

Davis, R. E., Vanover, K. E., Zhou, Y., et al. (2015). ITI-007 demonstrates brain occupancy at serotonin 5-HT(2)A and dopamine D(2) receptors and serotonin transporters using positron emission tomography in healthy volunteers. Psychopharmacology (Berl), 232, 2863–2872.CrossRefGoogle Scholar

Meyer, J. M. (2018). A concise guide to monoamine oxidase inhibitors: part 2. Current Psychiatry, 17, 22–33.Google Scholar

Meyer, J. M. (2018). Gilman: The Pharmacological Basis of Therapeutics. Pharmacotherapy of Psychosis and Mania. New York: McGraw-Hill.Google Scholar

Meyer, J. M. (2018). Pharmacotherapy of psychosis and mania. In Brunton, L. L., Hilal-Dandan, R., Knollmann, B. C. (eds.). Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 13th ed. Chicago, IL: McGraw-Hill, pp. 279–302.Google Scholar

Smith, D., Smith, R., Misquitta, D. (2016). Neuroimaging and violence. Psychiatr Clin North Am, 39, 579–597.CrossRefGoogle ScholarPubMed

Davidson, L. L., Heinrichs, R. W. (2003). Quantification of frontal and temporal lobe brain-imaging findings in schizophrenia: a meta-analysis. Psychiatry Res, 122, 69–87.CrossRefGoogle ScholarPubMed

Hill, K., Mann, L., Laws, K. R., et al. (2004). Hypofrontality in schizophrenia: a meta-analysis of functional imaging studies. Acta Psychiatr Scand, 110, 243–256.CrossRefGoogle ScholarPubMed

Sripada, C. S., Silk, K. R. (2007). The role of functional neuroimaging in exploring the overlap between borderline personality disorder and bipolar disorder. Curr Psychiatry Rep, 9, 40–45.CrossRefGoogle ScholarPubMed

McDermott, B. E., Holoyda, B. J. (2014). Assessment of aggression in inpatient settings. CNS Spectr, 19, 425–431.CrossRefGoogle ScholarPubMed

Poldrack, R. A., Monahan, J., Imrey, P. B., et al. (2018). Predicting violent behavior: what can neuroscience add? Trends Cogn Sci, 22, 111–123.CrossRefGoogle ScholarPubMed

Stahl, S. M., Morrissette, D. A., Cummings, M., et al. (2014). California State Hospital Violence Assessment and Treatment (Cal-VAT) guidelines. CNS Spectr, 19, 449–465.CrossRefGoogle ScholarPubMed

Meyer, J. M., Cummings, M. A., Proctor, G., et al. (2016). Psychopharmacology of persistent violence and aggression. Psychiatr Clin North Am, 39, 541–556.Google Scholar

Morrissette, D. A., Stahl, S. M. (2014). Treating the violent patient with psychosis or impulsivity utilizing antipsychotic polypharmacy and high-dose monotherapy. CNS Spectr, 19, 439–448.CrossRefGoogle ScholarPubMed

Cummings, M. A., Proctor, G. J., Arias, A. W. (2019). Dopamine antagonist antipsychotics in diverted forensic populations. CNS Spectr, in press, doi: 10.1017/S1092852919000841CrossRefGoogle Scholar

Citrome, L., Volavka, J. (2011). Pharmacological management of acute and persistent aggression in forensic psychiatry settings. CNS Drugs, 25, 1009–1021.CrossRefGoogle ScholarPubMed

Correll, C. U., Yu, X., Xiang, Y., et al. (2017). Biological treatment of acute agitation or aggression with schizophrenia or bipolar disorder in the inpatient setting. Ann Clin Psychiatry, 29, 92–107.Google ScholarPubMed

Levy, R. H., Friel, P. N., Johno, I., et al. (1984). Filtration for free drug level monitoring: carbamazepine and valproic acid. Ther Drug Monit, 6, 67–76.CrossRefGoogle ScholarPubMed

Keck, P. E., Jr., McElroy, S. L., Bennett, J. A. (1996). Health-economic implications of the onset of action of antimanic agents. J Clin Psychiatry, 57 13–18.Google ScholarPubMed

Leppik, I. E., Hovinga, C. A. (2013). Extended-release antiepileptic drugs: a comparison of pharmacokinetic parameters relative to original immediate-release formulations. Epilepsia, 54, 28–35.CrossRefGoogle ScholarPubMed

Plenge, P., Stensgaard, A., Jensen, H. V., et al. (1994). 24-hour lithium concentration in human brain studied by Li-7 magnetic resonance spectroscopy. Biol Psychiatry, 36, 511–516.CrossRefGoogle ScholarPubMed

Castro, V. M., Roberson, A. M., McCoy, T. H., et al. (2016). Stratifying risk for renal insufficiency among lithium-treated patients: an electronic health record study. Neuropsychopharmacol, 41, 1138–1143.Google Scholar

Malhi, G. S., Gessler, D., Outhred, T. (2017). The use of lithium for the treatment of bipolar disorder: recommendations from clinical practice guidelines. J Affect Disord, 217, 266–280.CrossRefGoogle ScholarPubMed

Chouinard, G. (2004). Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound. J Clin Psychiatry, 65, 7–12.Google ScholarPubMed

Amodeo, G., Fagiolini, A., Sachs, G., et al. (2017). Older and newer strategies for the pharmacological management of agitation in patients with bipolar disorder or schizophrenia. CNS Neurol Disord Drug Targets, 16, 885–890.Google ScholarPubMed

Liu, J., Chan, T. C. T., Chong, S. A., et al. (2019). Impact of emotion dysregulation and cognitive insight on psychotic and depressive symptoms during the early course of schizophrenia spectrum disorders. Early Interv Psychiatry, 14(6), 691–697.CrossRefGoogle ScholarPubMed

Walsh, M. T., Dinan, T. G. (2001). Selective serotonin reuptake inhibitors and violence: a review of the available evidence. Acta Psychiatr Scand, 104, 84–91.CrossRefGoogle ScholarPubMed

Beach, S. R., Kostis, W. J., Celano, C. M., et al. (2014). Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation. J Clin Psychiatry, 75, e441–449.CrossRefGoogle ScholarPubMed

Sanchez, C., Reines, E. H., Montgomery, S. A. (2014). A comparative review of escitalopram, paroxetine, and sertraline: are they all alike? Int Clin Psychopharmacol, 29, 185–196.CrossRefGoogle Scholar

Chiu, C. C., Lane, H. Y., Huang, M. C., et al. (2004). Dose-dependent alternations in the pharmacokinetics of olanzapine during coadministration of fluvoxamine in patients with schizophrenia. J Clin Pharmacol, 44, 1385–1390.CrossRefGoogle ScholarPubMed

Asnis, G. M., Thomas, M., Henderson, M. A. (2015). Pharmacotherapy treatment options for insomnia: a primer for clinicians. Int J Mol Sci, 17, 1–11.CrossRefGoogle ScholarPubMed

Ozdemir, P. G., Karadag, A. S., Selvi, Y., et al. (2014). Assessment of the effects of antihistamine drugs on mood, sleep quality, sleepiness, and dream anxiety. Int J Psychiatry Clin Pract, 18, 161–168.CrossRefGoogle ScholarPubMed

Jang, D. H., Manini, A. F., Trueger, N. S., et al. (2010). Status epilepticus and wide-complex tachycardia secondary to diphenhydramine overdose. Clin Toxicol (Phila), 48, 945–948.Google Scholar

Tonda, M. E., Guthrie, S. K. (1994). Treatment of acute neuroleptic-induced movement disorders. Pharmacotherapy, 14, 543–560.CrossRefGoogle ScholarPubMed

Ogino, S., Miyamoto, S., Miyake, N., et al. (2014). Benefits and limits of anticholinergic use in schizophrenia: focusing on its effect on cognitive function. Psychiatry Clin Neurosci, 68, 37–49.CrossRefGoogle ScholarPubMed

Praharaj, S. K., Kongasseri, S., Behere, R. V., et al. (2015). Mirtazapine for antipsychotic-induced acute akathisia: a systematic review and meta-analysis of randomized placebo-controlled trials. Ther Adv Psychopharmacol, 5, 307–313.CrossRefGoogle ScholarPubMed

Morkunas, B., Porritt, K., Stephenson, M. (2016). Experiences of mental health professionals and patients in the use of pro re nata medication in acute adult mental healthcare settings: a systematic review. JBI Database System Rev Implement Rep, 14, 209–250.CrossRefGoogle ScholarPubMed

Maiocchi, L., Bernardi, E. (2013). Optimisation of prescription in patients with long-term treatment-resistant schizophrenia. Australas Psychiatry, 21, 446–448.CrossRefGoogle ScholarPubMed

Remington, G., Addington, D., Honer, W., et al. (2017). Guidelines for the pharmacotherapy of schizophrenia in adults. Can J Psychiatry, 62, 604–616.Google Scholar

Patterson, T. L., Leeuwenkamp, O. R. (2008). Adjunctive psychosocial therapies for the treatment of schizophrenia. Schizophr Res, 100, 108–119.Google Scholar

Deutschenbaur, L., Lambert, M., Walter, M., et al. (2014). Long-term treatment of schizophrenia spectrum disorders: focus on pharmacotherapy. Nervenarzt, 85, 363–375.CrossRefGoogle ScholarPubMed